Get the Stockscreener App
9.10
7.44%
0.63
After Hours:
9.14
0.04
+0.44%
Bioventus Inc stock is traded at $9.10, with a volume of 925.92K.
It is up +7.44% in the last 24 hours and up +10.84% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$8.47
Open:
$9
24h Volume:
925.92K
Relative Volume:
3.41
Market Cap:
$609.49M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-15.17
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
+2.71%
1M Performance:
+10.84%
6M Performance:
+26.56%
1Y Performance:
-10.70%
1-Day Range:
$8.75
$9.53
1-Week Range:
$8.31
$9.53
52-Week Range:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.10 | 567.29M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com India
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus shares jump 7.6% on fourth-quarter earnings beat By Investing.com - Investing.com South Africa
Bioventus: Q4 Earnings Snapshot - KVUE
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS - TradingView
Bioventus (BVS) Exceeds Q4 Revenue Expectations, Eyes Future Gro - GuruFocus
Bioventus Q4 and Full Year 2025 Financial Results - TradingView
BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative
Bioventus beats Q4 estimates, guides 2026 revenue in line By Investing.com - Investing.com India
Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus beats Q4 estimates, guides 2026 revenue in line - Investing.com
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bioventus Q4 Earnings Assessment - Benzinga
Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions - TradingView
Bioventus Earnings Report: Q4 Overview - Benzinga
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Preview: Bioventus's Earnings - Benzinga
Bioventus Inc. $BVS Shares Bought by Royce & Associates LP - MarketBeat
Bioventus (BVS) versus Its Peers Critical Comparison - Defense World
Bioventus (NYSE:BVS) Stock Price Down 0.1%Should You Sell? - MarketBeat
Bioventus Inc. (BVS) Stock Analysis: Unpacking A 63.66% Potential Upside - DirectorsTalk Interviews
Reviewing Bioventus (BVS) and Its Peers - Defense World
BVS | Bioventus Inc. Class A FinancialsIncome Statement - Quiver Quantitative
Bioventus Inc. to Report Fourth Quarter Fiscal Year 2025 Financial Results on March 5, 2026 - Quiver Quantitative
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 - GlobeNewswire
BVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bioventus (BVS) versus The Competition Head to Head Comparison - Defense World
Can Bioventus Inc. generate free cash flow2025 Technical Patterns & Risk Adjusted Buy/Sell Alerts - mfd.ru
Bioventus Inc. (BVS) Investor Outlook: A 69% Potential Upside And Strong Analyst Ratings - DirectorsTalk Interviews
What is Bioventus Inc.’s valuation compared to sector2025 Bull vs Bear & Daily Growth Stock Tips - mfd.ru
Critical Analysis: Bioventus (BVS) versus The Competition - Defense World
Comparing Bioventus (BVS) & Its Peers - Defense World
Bioventus (BVS) vs. Its Rivals Head to Head Review - Defense World
Bioventus (BVS) SVP gets 4,375 shares, withholds 2,133 for tax - Stock Titan
Reviewing Bioventus (BVS) and The Competition - Defense World
Understanding Momentum Shifts in (BVS) - Stock Traders Daily
Bioventus (BVS) vs. Its Rivals Head to Head Survey - Defense World
Bioventus (BVS) & Its Peers Head-To-Head Survey - Defense World
Barrington Research Initiates Coverage of Bioventus (BVS) with Outperform Recommendation - Nasdaq
Bioventus (BVS) vs. Its Rivals Financial Analysis - Defense World
Risks Report: Is Bioventus Inc. a top pick in the sectorEntry Point & Daily Risk Controlled Trade Plans - mfd.ru
Will Bioventus Inc. stock outperform Nasdaq indexNew Guidance & Fast Exit Strategy with Risk Control - mfd.ru
Will Bioventus Inc. stock maintain growth storyTrade Analysis Summary & High Yield Stock Recommendations - mfd.ru
Volatility Watch: Is Bioventus Inc. a top pick in the sectorOptions Play & Weekly Setup with ROI Potential - mfd.ru
Bioventus Inc. (BVS): Investor Outlook on a Potential 79% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Head-To-Head Review: Bioventus (BVS) vs. Its Rivals - Defense World
Nantahala discloses 9.03% Bioventus (BVS) stake in Schedule 13G/A - Stock Titan
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):